Skip to main content

NASDAQ:BASI - Bioanalytical Systems Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: -26.53 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$23.14
▲ +0.45 (1.98%)
Get New Bioanalytical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BASI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.00
▼ -26.53% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Bioanalytical Systems in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a -26.53% upside from the last price of $23.14.

Buy

The current consensus among 1 investment analysts is to buy stock in Bioanalytical Systems.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2021Colliers SecuritiesReiterated RatingBuy$17.00Medium
i
Rating by K. Bauser at Colliers Securities
12/22/2020Colliers SecuritiesInitiated CoverageBuy$17.00High
i
Rating by K. Bauser at Colliers Securities
(Data available from 5/16/2016 forward)
Bioanalytical Systems logo
Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Read More

Today's Range

Now: $23.14
$22.64
$25.01

50 Day Range

MA: $18.71
$14.04
$22.50

52 Week Range

Now: $23.14
$3.05
$21.08

Volume

83,760 shs

Average Volume

122,925 shs

Market Capitalization

$257.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Bioanalytical Systems?

The following equities research analysts have issued stock ratings on Bioanalytical Systems in the last twelve months: Colliers Securities, and Zacks Investment Research.
View the latest analyst ratings for BASI.

What is the current price target for Bioanalytical Systems?

1 Wall Street analysts have set twelve-month price targets for Bioanalytical Systems in the last year. Their average twelve-month price target is $17.00, suggesting a possible downside of 26.5%. Colliers Securities has the highest price target set, predicting BASI will reach $17.00 in the next twelve months. Colliers Securities has the lowest price target set, forecasting a price of $17.00 for Bioanalytical Systems in the next year.
View the latest price targets for BASI.

What is the current consensus analyst rating for Bioanalytical Systems?

Bioanalytical Systems currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BASI will outperform the market and that investors should add to their positions of Bioanalytical Systems.
View the latest ratings for BASI.

What other companies compete with Bioanalytical Systems?

How do I contact Bioanalytical Systems' investor relations team?

Bioanalytical Systems' physical mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company's listed phone number is 765-463-4527 and its investor relations email address is [email protected] The official website for Bioanalytical Systems is www.basinc.com.